Loading…
Reported covered position: Office of Representative Gwen Graham (D-FL), Intern, 8/2016-12/2016 Horizon Therapetuics, Fellow, 6/2017-10/2017 California Life Science Association CLSA), Manager GA, 10/2017-4/2021
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ABIOMED, INC · Firm: ABIOMED, INC
Issues related to establishing heart recovery as the standard of care, Support for H.R. Res 1301 Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ABIOMED, INC · Firm: ABIOMED, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2024 · third_quarter · 3T
Issues related to establishing heart recovery as the standard of care, Support for H.R. Res 1301 Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to health equity and diversity in clinical trials Constituent issue follow-up
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Q2
Source: Senate LDA
Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Support for R&D expensing deduction for MedTech
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ABIOMED, INC · Firm: ABIOMED, INC
Issues related to establishing heart recovery as the standard of care, Support for H.R. Res 1301 Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to health equity and diversity in clinical trials Constituent issue follow-up
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ABIOMED, INC · Firm: ABIOMED, INC
Issues related to the implementation of the FDA Medical Device User Fee Agreement Issues related to heart recovery Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization Issues related to medical device supply chain and sterilization Issues related to healthcare work force development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ABIOMED, INC · Firm: ABIOMED, INC
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to IPPS rule making and changes related to external heart assist Issues related to medical device supply chain and sterilization Issues related to healthcare work force development Issues related to health equity and diversity in clinical trials FDA approval pathways for medical technologies Cardiovascular health
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ABIOMED, INC · Firm: ABIOMED, INC
Issues related to the implementation of the FDA Medical Device User Fee Agreement Issues related to heart recovery Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization Issues related to medical device supply chain and sterilization Issues related to healthcare work force development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ABIOMED, INC · Firm: ABIOMED, INC
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Health Care Prices Revealed and Information to Consumers Explained Transparency Act
Client: ABIOMED, INC · Firm: ABIOMED, INC
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Issues related to establishing heart recovery as the standard of care, Support for H.R. Res 1301 Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · first_quarter · Q1
Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Support for R&D expensing deduction for MedTech
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · fourth_quarter · Q4
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · third_quarter · Q3
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to IPPS rule making and changes related to external heart assist Issues related to medical device supply chain and sterilization Issues related to healthcare work force development Issues related to health equity and diversity in clinical trials FDA approval pathways for medical technologies Cardiovascular health
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Q2
Issues related to the implementation of the FDA Medical Device User Fee Agreement Issues related to heart recovery Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization Issues related to medical device supply chain and sterilization Issues related to healthcare work force development
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Q1
Issues related to the implementation of the FDA Medical Device User Fee Agreement Issues related to heart recovery Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization Issues related to medical device supply chain and sterilization Issues related to healthcare work force development
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Q4
- Issues relating to FDA medical device user fee reauthorization legislation (MDUFA) and the use of real world data - Education on heart recovery as the standard of care and increased diversity CV clinical trials - Issues relating to the supply chain for medical products - Issues related to Medicare coverage reform - Issues related to Health Equity
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Q3
- Issues relating to FDA user fee reauthorization and the use of real world data - Support heart recovery as the standard of care and increased diversity CV clinical trials - Issues relating to the supply chain for medical products - Education on FDA breakthrough medical device issues and use of RWE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · second_quarter · Q2
- Issues relating to FDA user fee reauthorization and the use of real world data - Support heart recovery as the standard of care and increased diversity CV clinical trials - Issues relating to the supply chain for medical products - Education on FDA breakthrough medical device issues and use of RWE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · first_quarter · Q1
- Issues relating to the reauthorization of MDUFA V - Education on the heart muscle recovery and support for continued diversity CV clinical trials - Issues relating to the supply chain for medical products - Education on FDA breakthrough medical device issues and use of RWE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Q4
- Issues relating to the reauthorization of the Medical Device User Fee and Modernization Act - Issues relating to heart recovery - Issues relating to the supply chain for medical products - Education on FDA Breakthrough Medical Device Issues and use of RWE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · third_quarter · Q3
- Issues relating to the reauthorization of the Medical Device User Fee and Modernization Act - Issues relating to heart recovery - Issues relating to the supply chain for medical products - Issues relating to R&D for medical devices and supporting competitive tax policies - Education on FDA Breakthrough Medical Device Issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Q2
- Issues relating to the reauthorization of the Medical Device User Fee and Modernization Act - Issues relating to heart recovery - Issues relating to the supply chain for medical products - Issues relating to R&D for medical devices and supporting competitive tax policies - Education on FDA Breakthrough Medical Device Issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE